Alirocumab's Price Reduction.

The article focuses on issues related to cost-effective pricing of Alirocumab and another PCSK9 inhibitor, evolocumab, which were priced at more than 14,000 dollars annually following the U.S. Food and Drug Administration's approval in 2015. It highlights the failure of these high prices to meet conventional cost-effectiveness thresholds with enormous budgetary implications raised by the widespread PCSK9 inhibitor adoption.